WuXi Biologics receives 2021 CMO Leadership Awards
25 February 2021 -

WuXi Biologics (2269.HK), a global company with open-access biologics technology platforms, announced on Wednesday that it has been named a winner of the 2021 CMO Leadership Awards.

The company has been recognised for the fourth consecutive year. It was honoured in six award categories, capabilities, compatibility, expertise, quality, reliability, and service, and across the respondent groups - Big Pharma, Small Pharma, and Overall (combined Big and Small Pharma).

The firm was chosen based on research from Industry Standard Research's Contract Manufacturing Quality Benchmarking annual online surveys with over 70 contract manufacturing organisations assessed on more than 23 different performance metrics. Research participants were recruited from Pharma and Biopharma companies of all sizes and were screened for decision-making influence related to working with contract manufacturing suppliers.